98%
921
2 minutes
20
Unlabelled: International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international cancer registry collecting data from 19 cancer centers, makes data from >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional real-world longitudinal clinical data, including treatment and outcome data, are being collected by the AACR Project GENIE Biopharma Collaborative using the PRISSMM data curation model. Several thousand of these cases are now also available in cBioPortal. We have significantly enhanced the functionalities of cBioPortal to support the visualization and analysis of this rich clinico-genomic linked dataset, as well as datasets generated by other centers and consortia. Examples of these enhancements include (i) visualization of the longitudinal clinical and genomic data at the patient level, including timelines for diagnoses, treatments, and outcomes; (ii) the ability to select samples based on treatment status, facilitating a comparison of molecular and clinical attributes between samples before and after a specific treatment; and (iii) survival analysis estimates based on individual treatment regimens received. Together, these features provide cBioPortal users with a toolkit to interactively investigate complex clinico-genomic data to generate hypotheses and make discoveries about the impact of specific genomic variants on prognosis and therapeutic sensitivities in cancer.
Significance: Enhanced cBioPortal features allow clinicians and researchers to effectively investigate longitudinal clinico-genomic data from patients with cancer, which will improve exploration of data from the AACR Project GENIE Biopharma Collaborative and similar datasets.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690089 | PMC |
http://dx.doi.org/10.1158/0008-5472.CAN-23-0816 | DOI Listing |
Prostate
September 2025
Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
Background: Genomic instability is a key feature of cancer and plays a central role in tumor progression. One emerging metric for genomic instability is the fraction of genome altered (FGA), which quantifies the proportion of the genome affected by copy number alterations. Previous studies in various solid tumors have shown that high FGA is associated with aggressive disease and adverse clinical outcomes.
View Article and Find Full Text PDFHealth Expect
October 2025
Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
Background: Breast cancer is a serious public health concern in Ghana. This study investigated the anticipated healthcare-seeking behaviour and preferences of women for possible breast cancer symptoms. Specifically, the study examined women's first point of contact as well as the timeliness of seeking healthcare for possible breast cancer symptoms.
View Article and Find Full Text PDFESMO Open
August 2025
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address:
Background: Immune checkpoint inhibitors (ICIs) have limited response rates in selected patients and can cause potentially life-threatening immune-related adverse events (irAEs). This underscores the urgent need for the development of biomarkers predictive of ICI response. Pre-existing autoantibodies (AAbs) have been linked with responses to ICIs and the development of irAEs.
View Article and Find Full Text PDFUrol Oncol
August 2025
Department of Urology, University of Florida College of Medicine, Jacksonville, FL. Electronic address:
Background: The role of genetic alterations (GAs) in renal cell carcinoma (RCC) accumulating over time remains unclear. We examined GAs by age group and their associations with overall survival (OS), immune infiltration, and immune checkpoint inhibitor (ICI) response.
Methods: Next-generation sequencing data from 3,360 RCC patients in the AACR Project GENIE registry were analyzed.
Nat Commun
July 2025
The ERC (Epi)Genetic Vulnerabilities in Solid Tumors and Sarcoma Laboratory, Inserm Unit UMR981, Gustave Roussy, Villejuif, France.
ADAR1 is an RNA editing enzyme which prevents autoimmunity by blocking interferon responses triggered by cytosolic RNA sensors, and is a potential target in immuno-oncology. However, predictive biomarkers for ADAR1 inhibition are lacking. Using multiple in vitro and in vivo systems, we show that BRCA1/2 and ADAR1 are synthetically lethal, and that ADAR1 activity is upregulated in BRCA1/2-mutant cancers.
View Article and Find Full Text PDF